Key result
Cardiac resynchronization therapy may benefit symptomatic heart failure patients with non-LBBB and QRS duration ≥ 150 ms, though evidence for typical RBBB and QRS < 150 ms remains limited.
Why the study?
It remains uncertain whether patients with heart failure and non-LBBB QRS morphology clearly benefit from cardiac resynchronization therapy or only modestly respond.
Does cardiac resynchronization therapy benefit patients with HFrEF and non-LBBB QRS morphology?
Does cardiac resynchronization therapy benefit patients with HFrEF and non-LBBB QRS morphology?
This review highlights the ongoing uncertainty regarding the magnitude of benefit of cardiac resynchronization therapy in HFrEF patients with non-LBBB QRS morphology compared to those with typical LBBB.
No takes yet. Share an insight, caveat, or question.
Caution against routine CRT in non-LBBB HFrEF; leaves open targeted trials for QRS ≥150 ms subgroups.
Henin et al. (2020) conducted a review in Heart failure with reduced ejection fraction (HFrEF) and non-LBBB QRS morphology. Cardiac resynchronization therapy (CRT) vs. Optimal medical therapy or ICD alone was evaluated. Cardiac resynchronization therapy may benefit symptomatic heart failure patients with non-LBBB and QRS duration ≥ 150 ms, though evidence for typical RBBB and QRS < 150 ms remains limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: